Core One Labs Inc. (CLABF)
USD 0.04
(-10.28%)
USD 0.04
(-10.28%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2022 | -7.79 Million CAD | 35.76% |
| 2021 | -12.13 Million CAD | -86.08% |
| 2020 | -6.52 Million CAD | 29.52% |
| 2019 | -9.25 Million CAD | 22.03% |
| 2018 | -11.86 Million CAD | 8.51% |
| 2017 | -12.97 Million CAD | -639.91% |
| 2016 | -1.75 Million CAD | -88.26% |
| 2015 | -931.17 Thousand CAD | -191.27% |
| 2014 | -319.69 Thousand CAD | -50.71% |
| 2013 | -212.13 Thousand CAD | 53.82% |
| 2012 | -459.33 Thousand CAD | -76.49% |
| 2011 | -260.26 Thousand CAD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 Q1 | -3.04 Million CAD | -39.06% |
| 2023 Q2 | -375 Thousand CAD | 87.68% |
| 2023 Q3 | -1.23 Million CAD | -228.88% |
| 2022 FY | - CAD | 35.76% |
| 2022 Q4 | -2.18 Million CAD | -103.19% |
| 2022 Q1 | -3.17 Million CAD | 86.96% |
| 2022 Q2 | -1.48 Million CAD | 53.33% |
| 2022 Q3 | -1.07 Million CAD | 27.37% |
| 2021 FY | - CAD | -86.08% |
| 2021 Q1 | -7.96 Million CAD | -275.33% |
| 2021 Q2 | 1.59 Million CAD | 120.09% |
| 2021 Q3 | 2.48 Million CAD | 55.35% |
| 2021 Q4 | -24.37 Million CAD | -1080.9% |
| 2020 Q2 | 263.94 Thousand CAD | 162.16% |
| 2020 Q3 | -2.28 Million CAD | -966.57% |
| 2020 Q4 | -2.12 Million CAD | 7.24% |
| 2020 FY | - CAD | 29.52% |
| 2020 Q1 | -424.63 Thousand CAD | 76.97% |
| 2019 Q2 | -2.48 Million CAD | -0.09% |
| 2019 FY | - CAD | 22.03% |
| 2019 Q4 | -1.84 Million CAD | 24.31% |
| 2019 Q1 | -2.48 Million CAD | 22.63% |
| 2019 Q3 | -2.43 Million CAD | 2.06% |
| 2018 Q4 | -3.21 Million CAD | 12.81% |
| 2018 FY | - CAD | 8.51% |
| 2018 Q2 | -2.84 Million CAD | -34.36% |
| 2018 Q1 | -2.12 Million CAD | 69.33% |
| 2018 Q3 | -3.68 Million CAD | -29.3% |
| 2017 Q2 | -886.28 Thousand CAD | -57.71% |
| 2017 Q1 | -561.97 Thousand CAD | -11.68% |
| 2017 Q4 | -6.91 Million CAD | -72.82% |
| 2017 FY | - CAD | -639.91% |
| 2017 Q3 | -4 Million CAD | -351.42% |
| 2016 Q2 | -314 Thousand CAD | -7.08% |
| 2016 Q3 | -642.54 Thousand CAD | -104.63% |
| 2016 Q4 | -503.2 Thousand CAD | 21.69% |
| 2016 FY | - CAD | -88.26% |
| 2016 Q1 | -293.24 Thousand CAD | -18.66% |
| 2015 Q2 | -282.99 Thousand CAD | -174.28% |
| 2015 Q4 | -247.13 Thousand CAD | 6.69% |
| 2015 Q3 | -264.85 Thousand CAD | 6.41% |
| 2015 FY | - CAD | -191.27% |
| 2015 Q1 | -103.17 Thousand CAD | 56.24% |
| 2014 Q3 | -101.18 Thousand CAD | -177.89% |
| 2014 Q1 | -56.87 Thousand CAD | 66.28% |
| 2014 Q2 | -36.41 Thousand CAD | 35.97% |
| 2014 FY | - CAD | -50.71% |
| 2014 Q4 | -235.76 Thousand CAD | -133.0% |
| 2013 Q2 | 114.15 Thousand CAD | 255.1% |
| 2013 FY | - CAD | 53.82% |
| 2013 Q1 | -73.59 Thousand CAD | 1.29% |
| 2013 Q3 | -84.05 Thousand CAD | -173.63% |
| 2013 Q4 | -168.64 Thousand CAD | -100.64% |
| 2012 Q3 | -74.29 Thousand CAD | 13.01% |
| 2012 Q1 | -225.07 Thousand CAD | -1543.14% |
| 2012 FY | - CAD | -76.49% |
| 2012 Q2 | -85.4 Thousand CAD | 62.06% |
| 2012 Q4 | -74.56 Thousand CAD | -0.36% |
| 2011 FY | - CAD | 0.0% |
| 2011 Q1 | -35.87 Thousand CAD | 0.0% |
| 2011 Q2 | -42.36 Thousand CAD | -18.11% |
| 2011 Q3 | -168.33 Thousand CAD | -297.32% |
| 2011 Q4 | -13.69 Thousand CAD | 91.86% |
| 2010 Q3 | -14.00 CAD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Nuo Therapeutics, Inc. | -3.06 Million USD | -154.493% |
| CNBX Pharmaceuticals Inc. | -3.54 Million USD | -119.768% |
| Mosaic ImmunoEngineering Inc. | -2.28 Million USD | -241.222% |
| Evofem Biosciences, Inc. | -17.37 Million USD | 55.123% |
| GB Sciences, Inc. | -1.41 Million USD | -449.0% |
| Inhibitor Therapeutics, Inc. | 378.84 Thousand USD | 2157.62% |
| NanoSphere Health Sciences Inc. | -12.22 Thousand USD | -63643.315% |
| Skye Bioscience, Inc. | -13.54 Million USD | 42.461% |
| Zenith Capital Corp. | -8.6 Million USD | 9.422% |
| Agentix Corp. | -1.37 Million USD | -468.262% |
| Arch Therapeutics, Inc. | -3.88 Million USD | -100.683% |
| Biomind Labs Inc. | -1.03 Million USD | -653.485% |
| ContraFect Corporation | -64.99 Million USD | 88.007% |
| CSL Limited | 4.78 Billion USD | 100.163% |
| CytoDyn Inc. | -18.02 Million USD | 56.763% |
| GlobeStar Therapeutics Corporation | 6724.00 USD | 116030.547% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -1132.621% |
| Northwest Biotherapeutics, Inc. | -55.33 Million USD | 85.914% |
| ProtoKinetix, Incorporated | -367.22 Thousand USD | -2022.746% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -407.482% |
| Regen BioPharma, Inc. | -936.94 Thousand USD | -731.974% |
| Santhera Pharmaceuticals Holding AG | 94.03 Million USD | 108.289% |
| SQZ Biotechnologies Company | -64.14 Million USD | 87.847% |
| Therapeutic Solutions International, Inc. | -1.48 Million USD | -424.076% |
| Eiger BioPharmaceuticals, Inc. | -71.03 Million USD | 89.026% |
| Intellipharmaceutics International Inc. | -2.64 Million USD | -194.775% |
| Mesoblast Limited | -62.38 Million USD | 87.506% |
| Marizyme, Inc. | -34.28 Million USD | 77.261% |
| Genus plc | 73.7 Million USD | 110.577% |
| Pharming Group N.V. | 9.87 Million USD | 178.922% |
| Nymox Pharmaceutical Corporation | -8.77 Million USD | 11.136% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -456.08% |
| IMV Inc. | -35.52 Million USD | 78.056% |
| AXIM Biotechnologies, Inc. | -2.32 Million USD | -235.446% |
| MultiCell Technologies, Inc. | -518.04 Thousand USD | -1404.725% |
| ONE Bio Corp. | 13.61 Million USD | 157.263% |
| RVL Pharmaceuticals plc | -48.22 Million USD | 83.837% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| Emmaus Life Sciences, Inc. | 3.57 Million USD | 318.23% |
| Provectus Biopharmaceuticals, Inc. | -2.89 Million USD | -169.512% |
| Oncotelic Therapeutics, Inc. | -7.16 Million USD | -8.852% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | -31080.68% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 50.88% |
| Alpha Cognition Inc. | -9.7 Million USD | 19.684% |
| Enzolytics Inc. | -2.12 Million USD | -267.345% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -216.02 Million USD | 96.392% |
| Enzon Pharmaceuticals, Inc. | 1.21 Million USD | 740.523% |
| Endonovo Therapeutics, Inc. | 8.85 Million USD | 188.043% |
| Genscript Biotech Corporation | -248.71 Million USD | 96.866% |
| Nanobac Pharmaceuticals, Incorporated | -5.92 Million USD | -31.477% |
| Institute of Biomedical Research Corp. | -239.15 Thousand USD | -3159.532% |
| Sigyn Therapeutics, Inc. | -2.44 Million USD | -218.63% |
| WPD Pharmaceuticals Inc. | -176.02 Thousand USD | -4328.461% |
| Cotinga Pharmaceuticals Inc. | -1.92 Million USD | -305.806% |
| VioQuest Pharmaceuticals, Inc. | -6.61 Million USD | -17.903% |
| PsyBio Therapeutics Corp. | -4.52 Million USD | -72.223% |
| Adynxx, Inc. | - USD | Infinity% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| Accustem Sciences Inc. | -3.74 Million USD | -108.07% |
| Helix BioMedix, Inc. | -1.04 Million USD | -645.014% |
| EV Biologics, Inc. | -1.26 Million USD | -515.182% |
| Q BioMed Inc. | -617.62 Thousand USD | -1162.114% |
| Capstone Therapeutics Corp. | -1.74 Million USD | -345.439% |
| American Oriental Bioengineering, Inc. | -39.63 Million USD | 80.334% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| BioStem Technologies, Inc. | -7.55 Million USD | -3.197% |
| Curative Biotechnology, Inc. | -2.5 Million USD | -211.562% |
| HST Global, Inc. | -5303.00 USD | -146895.474% |
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| Wesana Health Holdings Inc. | -2.05 Million USD | -278.958% |
| Halberd Corporation | -74.27 Thousand USD | -10394.447% |
| Resverlogix Corp. | -11.74 Million USD | 33.613% |
| Cell Source, Inc. | -4.27 Million USD | -82.449% |
| RespireRx Pharmaceuticals Inc. | -1.49 Million USD | -420.057% |
| GeneThera, Inc. | - USD | Infinity% |
| AVAX Technologies, Inc. | -6.11 Million USD | -27.525% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -44645.824% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| NovAccess Global Inc. | -1.03 Million USD | -653.304% |
| Kadimastem Ltd | -2.62 Million USD | -197.029% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Rasna Therapeutics, Inc. | -379.62 Thousand USD | -1953.414% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -181.08 Thousand USD | -4204.631% |
| LadRx Corporation | 412.28 Thousand USD | 1990.733% |
| Regen BioPharma, Inc. | 1.46 Million USD | 631.747% |
| Affymax, Inc. | -14.29 Million USD | 45.469% |
| Itoco Inc. | -1.86 Million USD | -317.078% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -598.492% |
| Mobile Lads Corp. | -2.24 Million USD | -247.819% |
| International Stem Cell Corporation | 202 Thousand USD | 3958.995% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| Bioxytran, Inc. | -3.82 Million USD | -104.054% |
| NDT Pharmaceuticals Inc. | -79.02 Thousand USD | -9763.683% |
| Qrons Inc. | -40.08 Thousand USD | -19348.542% |
| Alseres Pharmaceuticals, Inc. | -485.67 Thousand USD | -1505.008% |
| SYBLEU INC | -141.57 Thousand USD | -5406.191% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | 527.43 Thousand USD | 1577.945% |
| Rebus Holdings, Inc. | -951 Thousand USD | -719.681% |
| ImmunoCellular Therapeutics, Ltd. | -1.06 Million USD | -634.002% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -14708.454% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.46 Million USD | -216.628% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -35.86 Million USD | 78.268% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -45 Thousand USD | -17222.6% |
| Innovation Pharmaceuticals Inc. | -2.73 Million USD | -184.703% |
| Neutra Corp. | -181.24 Thousand USD | -4200.855% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | 61.332% |
| PureTech Health plc | -11.62 Million USD | 32.956% |
| Coeptis Therapeutics, Inc. | -20.15 Million USD | 61.329% |
| IXICO plc | -707 Thousand USD | -1002.57% |
| IntelGenx Technologies Corp. | -7.68 Million USD | -1.434% |
| Gelesis Holdings, Inc. | -48.34 Million USD | 83.876% |
| CSL Limited | 4.73 Billion USD | 100.165% |
| Cellectis S.A. | -92.63 Million USD | 91.585% |